文献速递甲状腺与颈部外科

透析继发性甲旁亢甲状旁腺切除术率上升

Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage.
PubMed 文献 · Surgery · 2022-03-21

基于美国肾脏数据系统2006至2016年379,835例维持性透析且以Medicare为主要支付方的成人继发性甲旁亢患者,采用多变量校正Poisson回归计算甲状旁腺切除术调整率比。10年随访中4,118例(1.1%)接受甲状旁腺切除术,拟钙剂使用增加3.5倍,甲状旁腺切除术率增加3.4倍;2014至2016年较2006至2009年切除率增加106%(调整率比=2.06,95%CI:1.90-2.24)。

要点

  • 379,835例透析继发性甲旁亢患者中4,118例(1.1%)接受甲状旁腺切除术。
  • 研究期内拟钙剂使用增加3.5倍,甲状旁腺切除术率增加3.4倍。
  • 2014至2016年切除率较2006至2009年增加106%(调整率比=2.06,95%CI:1.90-2.24)。

核心结论

  • 尽管药物治疗不断演变且拟钙剂使用增加,有Medicare覆盖的透析患者甲状旁腺切除术率仍持续上升。

研究设计与样本

  • 使用美国肾脏数据系统识别2006至2016年美国379,835例年龄≥18岁、维持性透析且以Medicare为主要支付方的成人患者,并确认其继发性甲旁亢治疗情况。
  • 采用多变量校正Poisson回归计算甲状旁腺切除术的调整率比。

主要发现

  • 379,835例继发性甲旁亢患者中,4,118例(1.1%)接受甲状旁腺切除术,39,835例(10.5%)接受西那卡塞,243,522例(64.1%)接受磷结合剂,17,571例(4.6%)接受维生素D类似物,86,899例(22.9%)在10年随访期间未接受治疗。
  • 整个研究期间拟钙剂使用增加3.5倍,甲状旁腺切除术率增加3.4倍。
  • 与2006至2009年相比,2010至2013年甲状旁腺切除术使用增加52%(调整率比=1.52,95%CI:1.39-1.65)。
  • 与2006至2009年相比,2014至2016年甲状旁腺切除术使用增加106%(调整率比=2.06,95%CI:1.90-2.24)。
  • 甲状旁腺切除术使用增幅最大的人群为较年轻患者(18-64岁)、黑人患者、女性患者、居住于较高贫困社区者、已列入肾移植等待名单者及居住于美国南部地区者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secondary hyperparathyroidism affects nearly all patients with renal failure on dialysis. Medical treatment of secondary hyperparathyroidism has considerably evolved over the past 2 decades, with parathyroidectomy reserved for severe cases. The primary objective of our study was to understand how trends in medical treatments affected parathyroidectomy rates in patients with secondary hyperparathyroidism on dialysis. METHODS: We used the United States Renal Data System to identify 379,835 adult patients (age ≥18) who were on maintenance dialysis in the United States between 2006 and 2016 with Medicare as the primary payor and ascertained treatment for secondary hyperparathyroidism. Adjusted rate ratios for rates of parathyroidectomy were calculated using multivariable-adjusted Poisson regression. RESULTS: Of 379,835 secondary hyperparathyroidism patients, 4,118 (1.1%) underwent parathyroidectomy, 39,835 (10.5%) received cinacalcet, 243,522 (64.1%) received phosphate binders, 17,571 (4.6%) received vitamin D analogs, and 86,899 (22.9%) received no treatment during the 10 years of follow-up. Over the entire study period, there was a 3.5-fold increase in the use of calcimimetics and a 3.4-fold increase in rates of parathyroidectomy. Compared to 2006 through 2009, utilization of parathyroidectomy increased 52% (adjusted rate ratio = 1.52, 95% confidence interval: 1.39-1.65) between 2010 and 2013 and by 106% (adjusted rate ratio = 2.06, 95% confidence interval: 1.90-2.24) between 2014 and 2016. The greatest increase in parathyroidectomy utilization occurred in younger patients (age 18-64 years), Black patients, female patients, those living in higher poverty neighborhoods, those listed for kidney transplant, and those who live in the Southern region of the United States. CONCLUSION: Despite the evolution of medical treatments and an increase in the use of calcimimetics to treat secondary hyperparathyroidism, parathyroidectomy rates have been steadily increasing among dialysis patients with Medicare coverage.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Mathur A, Ahn JB, Sutton W, et al. Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage. Surgery. 2022. PMID: 35314072. doi:10.1016/j.surg.2022.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。